Search Results


Your search for Kenneth C. Anderson, MD matches 57 pages

Showing 51 - 57

skin cancer
breast cancer
multiple myeloma
colorectal cancer
prostate cancer
pancreatic cancer

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2015 Updates

For 2 decades, the NCCN Guidelines® have been recognized as the standard of cancer care in the United States, combining evidence, experience, and choice, so that multidisciplinary cancer treatment teams—including patients—are empowered to make informed decisions about cancer care,” said Robert W....


A Lasting Legacy

When Emil J Freireich, MD, retires from the University of Texas MD Anderson Cancer Center on September 1, he will have spent 50 years at the institution and a total of 60 years in the pursuit of curing childhood leukemia as well as other cancers and in the educational development of young...

Seventeen ASTRO Members Awarded Fellows Designation

The American Society for Radiation Oncology (ASTRO) has selected 17 distinguished members to receive the ASTRO Fellows designation. The 2015 class of Fellows will receive the recognition at the Awards Ceremony at ­ASTRO’s 57th Annual Meeting on Tuesday, October 20 in San Antonio, Texas. ASTRO...

issues in oncology

Alfred Goldberg, PhD, and Paul Richardson, MD, to Present 2015 ASH Ernest Beutler Lecture

The American Society of Hematology (ASH) will honor Alfred Goldberg, PhD, of Harvard Medical School, and Paul Richardson, MD, of Dana-Farber Cancer Institute, with the 2015 Ernest Beutler Lecture and Prize for their significant research advances in the area of proteasome inhibitors and their...

Cancer Researchers and Clinicians Elected as 2015 AAAS Fellows

The American Association for the Advancement of Science (AAAS) Council elected 347 fellows for 2015, in recognition of their contributions to innovation, education, and scientific leadership. The tradition of electing AAAS fellows began in 1874 to recognize members for their scientifically or...

hematologic malignancies

Preclinical Study Looks at RNA Polymerase I Inhibitor in Refractory AML and Multiple Myeloma

A laboratory study of the investigational drug CX-5461, which blocks the inhibition of RNA polymerase I transcription, has found that it prolonged survival in mouse models of highly aggressive acute myeloid leukemia (AML) and multiple myeloma refractory to standard therapy. In addition, the...


Tyrosine Kinase Inhibitors May Improve Treatment Outcomes in Children With Philadelphia Chromosome–Like ALL

Using genomic profiling and next-generation sequencing of patients with BCR-ABL1-like B-progenitor acute lymphoblastic leukemia (B-cell ALL) and Philadelphia chromosome–like ALL, researchers recently identified alterations targeting 18 kinase or cytokine receptor genes. They then determined...